N9 Engineered cells in skin disease (Voskens)
Dressing up and ready to move: Engineered immune cells for treatment of autoimmune skin diseases
Term: 01.07.2024 – 30.06.2026
We hypothesize that, during inflammation, a highly motile subset of lymphocytes, including T cells, B cells and regulatory T cells migrates from the blood into the skin. The characterization of this highly motile subset would allow us to identify the migration and suppressive molecules selectively employed by these cells to reach the site of inflammation. We propose that we can engineere blood-derived immune cells with these molecules. In such a scenario, these engineered immune cells are highly migratory and ready to move to the site of inflammation after adoptive cell transfer.
